Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Annual report

4886.TEDINET S100OHVN
Period2021-04-01 → 2022-03-31
Filed2022-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 37
MetricValuePeriodScopeSource row
Revenue¥56.6bn2021-04-01 → 2022-03-31Cons.Net sales
Operating income¥4.8bn2021-04-01 → 2022-03-31Cons.Operating income
Ordinary income¥4.9bn2021-04-01 → 2022-03-31Cons.Ordinary income
Profit before tax¥6.2bn2021-04-01 → 2022-03-31Cons.Income before income taxes
Net income (owners)¥4.3bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent
Net income¥4.3bn2021-04-01 → 2022-03-31Cons.Profit loss
Total assets¥83.3bnat 2022-03-31Cons.Assets
Total liabilities¥34.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥48.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥44.5bnat 2021-03-31Cons.Net assets
Cash and deposits¥12.1bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥17.1bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥10.5bnat 2021-03-31Cons.Cash and cash equivalents
Operating cash flow¥2.8bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities
Investing cash flow¥6.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥3.0bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities
EPS (basic)¥151.222021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
Net assets per share¥1,734.8at 2022-03-31Cons.Net assets per share (5-year summary)
Equity ratio58.7%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
ROE8.8%2021-04-01 → 2022-03-31Cons.Rate of return on equity (5-year summary)
Employees777at 2022-03-31Cons.Number of employees
Revenue¥1.4bn2021-04-01 → 2022-03-31StandaloneOperating revenue1
Operating income¥717m2021-04-01 → 2022-03-31StandaloneOperating income
Ordinary income¥717m2021-04-01 → 2022-03-31StandaloneOrdinary income
Profit before tax¥717m2021-04-01 → 2022-03-31StandaloneIncome before income taxes
Net income¥682m2021-04-01 → 2022-03-31StandaloneProfit loss
Total assets¥41.3bnat 2022-03-31StandaloneAssets
Total liabilities¥606mat 2022-03-31StandaloneLiabilities
Net assets / equity¥40.7bnat 2022-03-31StandaloneNet assets
Cash and deposits¥820mat 2022-03-31StandaloneCash and deposits
EPS (basic)¥23.792021-04-01 → 2022-03-31StandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥152021-04-01 → 2022-03-31StandaloneDividend paid per share (5-year summary)
Net assets per share¥1,443.94at 2022-03-31StandaloneNet assets per share (5-year summary)
Equity ratio98.5%at 2022-03-31StandaloneEquity to asset ratio (5-year summary)
ROE1.7%2021-04-01 → 2022-03-31StandaloneRate of return on equity (5-year summary)
Shares issued30,563,199at 2022-03-31StandaloneTotal number of issued shares (5-year summary)
Employees74at 2022-03-31StandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 24
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsdepreciation2021-04-01 → 2022-03-31¥5m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsemployeesat 2022-03-3148 pure
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2022-03-31¥5.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2022-03-31¥5.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2022-03-31¥73m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2022-03-31¥3.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2022-03-31¥360m
Reconciling Itemsreconcilingdepreciation2021-04-01 → 2022-03-31¥136m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2022-03-31−¥73m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2022-03-31−¥73m
Reconciling Itemsreconcilingsegment assetsat 2022-03-31¥37.3bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2022-03-31−¥653m
Pharmaceutical Businessreportable segmentdepreciation2021-04-01 → 2022-03-31¥2.5bn
Pharmaceutical Businessreportable segmentemployeesat 2022-03-31649 pure
Pharmaceutical Businessreportable segmentrevenue2021-04-01 → 2022-03-31¥50.8bn
Pharmaceutical Businessreportable segmentrevenue external2021-04-01 → 2022-03-31¥50.8bn
Pharmaceutical Businessreportable segmentsegment assetsat 2022-03-31¥42.9bn
Pharmaceutical Businessreportable segmentsegment profit2021-04-01 → 2022-03-31¥5.1bn
Total Of Reportable Segments And Otherssegment totaldepreciation2021-04-01 → 2022-03-31¥2.6bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2022-03-31¥56.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2022-03-31¥56.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2022-03-31¥73m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2022-03-31¥46.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2022-03-31¥5.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,041
ItemContextValueUnit
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_LegalCapitalSurplusMember844000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_OtherCapitalSurplusMember41239000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_CapitalSurplusMember42084000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_RetainedEarningsBroughtForwardMember747000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_RetainedEarningsMember747000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_TreasuryStockMember-3335000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember40695000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember40695000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_CapitalStockMember1197000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_LegalCapitalSurplusMember844000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_OtherCapitalSurplusMember41239000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_CapitalSurplusMember42084000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_RetainedEarningsBroughtForwardMember747000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_RetainedEarningsMember747000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_TreasuryStockMember-3335000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_ShareholdersEquityMember40695000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember40695000000JPY
Salaries allowances and bonuses sgaCurrentYearDuration_NonConsolidatedMember287000000JPY
Provision for bonuses sgaCurrentYearDuration_NonConsolidatedMember60000000JPY
Retirement benefit expenses sgaCurrentYearDuration_NonConsolidatedMember29000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2022-06-28
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第１期（自　2021年４月１日　至　2022年３月31日）
Company name cover pageFilingDateInstant
Original text (Japanese)あすか製薬ホールディングス株式会社
Company name in english cover pageFilingDateInstantASKA Pharmaceutical Holdings Co., Ltd.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　山口　隆
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区芝浦二丁目５番１号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)（03）5484－8845（代表）
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)グループ経理部長　　市川　学
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区芝浦二丁目５番１号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)（03）5484－8845（代表）
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)グループ経理部長　　市川　学
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE35791
Fund codeFilingDateInstant－
Security codeFilingDateInstant48860
Filer name in japaneseFilingDateInstant
Original text (Japanese)あすか製薬ホールディングス株式会社
Filer name in englishFilingDateInstantASKA Pharmaceutical Holdings Co., Ltd.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstanttrue
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Current fiscal year start dateFilingDateInstant2021-04-01
Current period end dateFilingDateInstant2022-03-31

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identitynon_consolidated 2022-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2022-03-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2022-03-31pass
statement vs summary · revenueconsolidated 2021-04-01/2022-03-31pass
statement vs summary · revenuenon_consolidated 2021-04-01/2022-03-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsnon_consolidated 2022-03-31pass